Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alphamab Oncology ( (HK:9966) ) has provided an update.
Alphamab Oncology has appointed Dr. Wang Hongwei as chief technology officer, tasking him with overseeing process and analytical development, production and quality for the company’s biologic drug portfolio. Dr. Wang brings extensive CMC and commercial manufacturing expertise, having led approvals and commercialization of multiple innovative biologics and advanced over 20 candidates into pivotal clinical stages.
His previous senior roles at Jiangsu Hengrui Pharmaceuticals and its biopharmaceutical subsidiaries, along with his regulatory and lifecycle management experience, are expected to strengthen Alphamab’s capabilities in scaling biologics development and manufacturing. The appointment underscores the company’s efforts to enhance operational execution in oncology biologics and could support smoother advancement of its pipeline toward late-stage development and commercialization.
The most recent analyst rating on (HK:9966) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
More about Alphamab Oncology
Alphamab Oncology is a Hong Kong-listed biopharmaceutical company focused on the research, development and manufacturing of innovative biologic drugs for oncology. The company operates across the full lifecycle of biologics, from process and analytical development through to large-scale commercial production, targeting cancer treatment markets in China and globally.
Average Trading Volume: 1,453,364
Technical Sentiment Signal: Sell
Current Market Cap: HK$7.8B
Find detailed analytics on 9966 stock on TipRanks’ Stock Analysis page.